AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback
AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.